Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.46 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10203775 | 0.86 | NOTUM (0.53) | NOTUMKMT2ATSHRRAB9AL3MBTL1 | |
| SCHEMBL14683431 | 0.84 | NOTUM (0.47) | NOTUMKMT2ATSHRRAB9AL3MBTL1 | |
| SCHEMBL10165373 | 0.84 | NOTUM (0.47) | NOTUMKMT2ATSHRRAB9AL3MBTL1 | |
| SCHEMBL3374081 | 0.84 | NOTUM (0.47) | NOTUMKMT2ATSHRRAB9AL3MBTL1 | |
| SCHEMBL11412911 | 0.81 | KMT2A (0.49) | NOTUMKMT2ATSHRRAB9AL3MBTL1 | |
| SCHEMBL2182449 | 0.81 | NR3C2 (0.53) | NOTUMKMT2ASLC6A4SLC6A2CYP1A2 | |
| SCHEMBL6706690 | 0.79 | PTPN1 (0.44) | NOTUMKMT2ARAB9AL3MBTL1SLC6A4 | |
| SCHEMBL1967791 | 0.78 | SLC6A4 (0.47) | NOTUMKMT2ATSHRRAB9AL3MBTL1 | |
| SCHEMBL6258605 | 0.78 | HTR2A (0.45) | SLC6A4SLC6A2 | |
| SCHEMBL2002647 | 0.78 | PTGS2 (0.38) | KMT2ANTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509424-A1 | NOVEL OXADIAZOLE COMPOUNDS | Abbott Laboratories (US) | 2012-10-17 | — | — | EP | claimed |
| WO-2011071570-A1 | NOVEL OXADIAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-16 | — | — | WO | claimed |
| CN-110621766-B | Dispersant, method of manufacture and use thereof | 雪佛龙奥伦耐有限责任公司 | 2021-12-24 | — | — | CN | disclosed |
| CN-110621766-A | Dispersant, method of manufacture and use thereof | 雪佛龙奥伦耐有限责任公司 | 2019-12-27 | — | — | CN | disclosed |
| US-8492403-B2 | Bicyclic derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-23 | — | — | US | disclosed |
| US-20130131109-A1 | BICYCLIC DERIVATIVES AS MODULATORS OF VOLTAGE GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-23 | — | — | US | disclosed |
| US-8357702-B2 | Bicyclic derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-22 | — | — | US | disclosed |
| US-20120308606-A1 | BICYCLIC DERIVATIVES AS MODULATORS OF VOLTAGE GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-06 | — | — | US | disclosed |
| EP-2509424-A1 | NOVEL OXADIAZOLE COMPOUNDS | Abbott Laboratories (US) | 2012-10-17 | — | — | EP | disclosed |
| US-8236829-B2 | Bicyclic derivatives as modulators of voltage gated ION channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-07 | — | — | US | disclosed |
| WO-2012014186-A1 | PROCESS FOR THE PREPARATION OF SILODOSIN AND ITS NOVEL INTERMEDIATES | RANBAXY LABORATORIES LIMITED (IN) | 2012-02-02 | — | — | WO | disclosed |
| WO-2011071570-A1 | NOVEL OXADIAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-16 | — | — | WO | disclosed |
| US-20110112156-A1 | Bicyclic Derivatives as Modulators of Voltage Gated ION Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-05-12 | — | — | US | disclosed |
| US-7855220-B2 | Bicyclic derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-21 | — | — | US | disclosed |
| EP-1833787-A2 | INDOLE DERIVATIVES FOR USE AS PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2007-09-19 | — | — | EP | disclosed |
| US-20070203130-A1 | Bicyclic derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-30 | — | — | US | disclosed |
| US-20060135540-A1 | PPAR active compounds | PLEXXIKON, INC. | 2006-06-22 | — | — | US | disclosed |
| WO-2006060535-A2 | INDOLE DERIVATIVES FOR USE AS PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120308606-A1 | BICYCLIC DERIVATIVES AS MODULATORS OF VOLTAGE GATED ION CHANNELS | TRPV1, TRPV2, TRPV3 | NOTUM 3398/4885KMT2A 3438/4885TSHR 4140/4885 |
| US-20070203130-A1 | Bicyclic derivatives as modulators of voltage gated ion channels | TRPV1, TRPV2, TRPV3 | NOTUM 3398/4885KMT2A 3438/4885TSHR 4140/4885 |
| US-20130131109-A1 | BICYCLIC DERIVATIVES AS MODULATORS OF VOLTAGE GATED ION CHANNELS | TRPV1, TRPV2, TRPV3 | NOTUM 3398/4885KMT2A 3438/4885TSHR 4140/4885 |
| US-20110112156-A1 | Bicyclic Derivatives as Modulators of Voltage Gated ION Channels | TRPV1, TRPV2, TRPV3 | NOTUM 3398/4885KMT2A 3438/4885TSHR 4140/4885 |
| US-20060135540-A1 | PPAR active compounds | PPARG, PPARA, PPARD | NOTUM 846/4885KMT2A 4098/4885TSHR 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.